Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 266Lung Neoplasms 102Adenocarcinoma of Lung 28Mesothelioma, Malignant 24Mesothelioma 22Neoplasms 18Meningeal Carcinomatosis 18Brain Neoplasms 16Head and Neck Neoplasms 14Neoplasm Metastasis 13Ovarian Neoplasms 9NSCLC 9Colorectal Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 8Breast Neoplasms 7Recurrence 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma 5Esophageal Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Sarcoma 4Non-squamous Non-small Cell Lung Cancer 4Non-small Cell Lung Cancer Metastatic 4Fallopian Tube Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3

Interventions

zipalertinib 1Specimen Handling 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Non-Squamous Non-Small Cell Carcinoma × Pemetrexed × Clear all
NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
16 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡